Balaxi Pharmaceuticals Peer Comparison

NSE: BALAXI

₹22.34

₹-0.20 (-0.89%)

As on 31-Aug-2026IST

Market cap

₹123 Cr

Revenue (TTM)

₹280 Cr

P/E Ratio

50.9

P/B Ratio

0.5

Div. Yield

0 %

Edit

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	123	30,606	30,088	28,551	25,816
Revenue (₹ Cr)	280	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	2.42	414.00	288.22	-371.81	387.35
Net Margin (%)	0.85	11.23	14.79	-3.93	26.01
RoE (%)	0.99	8.38	29.77	-3.85	25.18
Price to Earnings	50.88	74.83	104.39	--	66.84
Price-To-Book	0.49	6.08	22.41	3.57	14.93

Income Statement (₹ Cr)

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	280.11	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	283.72	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	271.07	2,792.00	1,485.56	8,195.15	919.25
EBITDA	9.04	772.00	450.24	1,010.13	542.56
Depreciation	2.54	226.00	50.83	857.51	37.68
EBIT	6.50	546.00	399.41	152.62	504.88
Interest	3.63	217.00	40.84	342.73	3.77
Other Income	3.61	122.00	12.78	244.31	27.45
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	6.48	463.00	371.35	-162.68	528.56
Provision for Tax	4.06	49.00	83.14	209.13	141.21
Profit after Tax	2.42	414.00	288.22	-371.81	387.35

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	249.08	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	25.80	1,712.00	202.03	5,044.14	42.40
Current Liabilities	62.16	1,622.00	835.87	4,758.28	230.82
Total Liabilities	337.03	8,578.00	2,326.71	17,723.32	1,983.96

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	81.68	5,343.00	519.60	10,211.52	1,026.85
Current Assets	251.43	2,606.00	1,681.81	7,191.66	881.27
Total Assets	337.03	8,578.00	2,326.71	17,723.32	1,983.96
Total Debt*	55.79	2,125.00	259.37	5,495.48	26.49
Net Current Assets	189.27	984.00	845.94	2,433.38	650.46
Contingent Liabilities	--	768.26	19.09	95.72	17.25

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-4.50	390.00	205.05	1,652.60	292.17
Cash Flow from Investing Activities	-20.78	-241.00	-409.72	-826.03	-265.94
Cash from Financing Activities	0.44	-54.00	283.07	-38.98	4.10
Net Cash Inflow / Outflow	-24.84	95.00	78.39	787.59	30.33

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	3.48	6.79	29.22	1.24	32.42
ROE (%)	0.99	8.38	29.77	-3.85	25.18
ROA (%)	0.75	4.94	24.77	-2.21	21.93
EBIT Margin (%)	2.32	15.32	20.63	1.66	34.54
Net Margin (%)	0.85	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-5.90	18.37	46.65	0.78	40.90
EBIT Growth (%)	-77.90	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	-87.18	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	-87.18	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	7.48	13.47	144.31	0.33	26.03

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	50.94	76.81	102.79	-91.24	66.84
Price / Book Value	0.49	6.08	22.41	3.57	14.93
Dividend Yield (%)	0.00	0.00	0.08	0.00	0.08
EV/EBITDA	18.20	41.54	66.63	32.36	47.22
Market Cap (₹ Cr)	86.51	19,071.62	12,753.19	18,108.89	20,944.75

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.09	0.31	0.11	0.53	0.02
Short term debt to equity ratio	0.13	0.09	0.05	0.09	0.02
Current Ratio	4.05	1.61	2.01	1.51	3.82
Quick Ratio	2.70	1.06	1.14	0.87	2.82
Interest Coverage	2.78	3.13	10.09	0.53	141.16

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	48.59	16.50	26.28	23.44	24.80
Asset Turnover	0.87	0.43	1.66	0.55	0.83
Receivable days	166.78	58.75	40.13	78.20	88.98
Inventory Days	109.40	75.82	60.29	93.30	56.04
Payable days	45.22	186.21	232.47	226.14	99.95
Cash Conversion Cycle	230.96	-51.64	-132.04	-54.64	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.